Jasper Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Jasper Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($18.74M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($26.72M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($21.24M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($18.64M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($14.58M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($13.73M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($47.88M) | Nov 7, 2024 |
| Q3 | 2023 | Jun 30, 2023 | ($16.08M) | Nov 9, 2023 |
| Q2 | 2024 | Jun 30, 2023 | ($16.08M) | Aug 13, 2024 |
| Q2 | 2023 | Mar 31, 2023 | ($14.26M) | Aug 11, 2023 |
| Q1 | 2024 | Mar 31, 2023 | ($14.26M) | May 14, 2024 |
| Q3 | 2023 | Mar 31, 2023 | ($14.26M) | Nov 9, 2023 |
| Q3 | 2023 | Sep 30, 2022 | ($11.86M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($10.40M) | Aug 11, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($10.40M) | Nov 9, 2023 |
| Q3 | 2023 | Mar 31, 2022 | ($2.21M) | Nov 9, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($2.21M) | May 12, 2023 |
| Q2 | 2023 | Mar 31, 2022 | ($2.21M) | Aug 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($3.41M) | Nov 10, 2022 |
| Q3 | 2022 | Jun 30, 2021 | ($8.41M) | Nov 10, 2022 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($19.17M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($27.08M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($21.80M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($19.89M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($15.99M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($15.07M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($19.36M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($17.83M) | Aug 13, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($13.95M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($12.71M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($11.96M) | Aug 11, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($12.78M) | May 12, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($10.08M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($8.42M) | Aug 12, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($6.25M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($6.01M) | Nov 12, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($327.6K) | Aug 16, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($228.7K) | May 24, 2021 |
| Q3 | 2020 | Aug 30, 2019 | ($1.0K) | Nov 10, 2020 |